Cohort study on testicular cancer follow-up strategies
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
This study looks at different ways to check for any return of testicular cancer in patients who are in complete remission to see which methods work best for their follow-up care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6900 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Cantonal Hospital of St. Gallen Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Sankt Gallen) |
| Trial ID | NCT02229916 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of various diagnostic tests and follow-up strategies for patients with testicular cancer who have achieved complete remission. It focuses on the early detection of relapses using methods such as radiographs, CT scans, and serum tumor markers, while also assessing the patterns of care and long-term outcomes for these patients. The study seeks to standardize follow-up procedures to improve patient care and minimize unnecessary interventions. By collecting data on treatment sequelae and patient characteristics, the study aims to enhance understanding of the disease's impact on survivors.
Who should consider this trial
Good fit: Ideal candidates include young men with histologically proven seminomas or non-seminomas who have recently completed treatment and are in complete remission.
Not a fit: Patients with co-existing malignancies or those unable to comply with follow-up schedules may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved follow-up protocols that enhance early relapse detection and reduce unnecessary treatments for testicular cancer survivors.
How similar studies have performed: Other studies have shown success in improving follow-up strategies for testicular cancer, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent. * Histologically proven seminomas or non-seminoma. * Seminoma: complete remission (CR) or lymph nodes (LN) \< 3cm or PET negative partial remission (PR) or non-seminoma: CR. * Completion of treatment within the last 6 months. * Patient able and willing to attend for regular surveillance. Exclusion Criteria: * Co-existent malignancy within 5 years. * Inability for any reason to comply with the trial investigations or follow-up schedules.
Where this trial is running
Sankt Gallen
- Kantonsspital St.Gallen; Onkologie/Haematologie — Sankt Gallen, Switzerland (Recruiting)
Study contacts
- Principal investigator: Christian Rothermundt, Dr. med. — Cantonal Hospital of St. Gallen
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.